These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 11860405)
41. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Cremonini F; Camilleri M; Vazquez Roque M; McKinzie S; Burton D; Baxter K; Zinsmeister AR Gastroenterology; 2006 Nov; 131(5):1431-9. PubMed ID: 17101319 [TBL] [Abstract][Full Text] [Related]
42. Does the nutrient drink test accurately predict postprandial gastric volume in health and community dyspepsia? Gonenne J; Castillo EJ; Camilleri M; Burton D; Thomforde GM; Baxter KL; Zinsmeister AR Neurogastroenterol Motil; 2005 Feb; 17(1):44-50. PubMed ID: 15670263 [TBL] [Abstract][Full Text] [Related]
43. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509 [TBL] [Abstract][Full Text] [Related]
44. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696 [TBL] [Abstract][Full Text] [Related]
45. Feasibility and application of 3-dimensional ultrasound for measurement of gastric volumes in healthy adults and adolescents. Manini ML; Burton DD; Meixner DD; Eckert DJ; Callstrom M; Schmit G; El-Youssef M; Camilleri M J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):287-93. PubMed ID: 19274782 [TBL] [Abstract][Full Text] [Related]
46. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. Saslow SB; Scolapio JS; Camilleri M; Forstrom LA; Thomforde GM; Burton DD; Rubin J; Pitot HC; Zinsmeister AR Gut; 1998 May; 42(5):628-34. PubMed ID: 9659155 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088 [TBL] [Abstract][Full Text] [Related]
48. Dietary influence on electro-gastrography and association of alterations in gastric myoelectrical activity with symptoms in patients with functional dyspepsia. Lee KJ; Kim JH; Cho SW J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):59-64. PubMed ID: 16706813 [TBL] [Abstract][Full Text] [Related]
49. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587 [TBL] [Abstract][Full Text] [Related]
50. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Houghton LA; Foster JM; Whorwell PJ Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662 [TBL] [Abstract][Full Text] [Related]
51. Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Di Stefano M; Vos R; Klersy C; Lee KJ; Janssens J; Tack J Am J Gastroenterol; 2006 Dec; 101(12):2797-804. PubMed ID: 17227525 [TBL] [Abstract][Full Text] [Related]
52. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472 [TBL] [Abstract][Full Text] [Related]
53. Relationship between partial gastric volumes and dyspeptic symptoms in fundoplication patients: a 3D ultrasonographic study. Scheffer RC; Gooszen HG; Wassenaar EB; Samsom M Am J Gastroenterol; 2004 Oct; 99(10):1902-9. PubMed ID: 15447748 [TBL] [Abstract][Full Text] [Related]
54. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597 [TBL] [Abstract][Full Text] [Related]
55. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Bisschops R; Karamanolis G; Arts J; Caenepeel P; Verbeke K; Janssens J; Tack J Gut; 2008 Nov; 57(11):1495-503. PubMed ID: 18519430 [TBL] [Abstract][Full Text] [Related]
56. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. Andrews CN; Bharucha AE; Camilleri M; Low PA; Seide BM; Burton DD; Nickander KK; Baxter KL; Zinsmeister AR Neurogastroenterol Motil; 2007 Sep; 19(9):716-23. PubMed ID: 17727392 [TBL] [Abstract][Full Text] [Related]
57. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028 [TBL] [Abstract][Full Text] [Related]